Schedule 13D ownership disclosure

Innate Pharma SA

Ordinary Shares, nominal value EUR0.05 per share · CUSIP: 45781K105

Event date: 2025-04-25

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Bpifrance Participations S.A.Reported CIK 0001581835

    Shares: 6,389,406.00 · Class: 6.9%

  • CDC Croissance S.A.

    Shares: 930,023.00 · Class: 1.0%

  • Caisse des depots et consignationsReported CIK 0001056947

    Shares: 7,319,429.00 · Class: 7.9%

  • EPIC Bpifrance

    Shares: 6,389,406.00 · Class: 6.9%

  • Bpifrance S.A.Reported CIK 0001731118

    Shares: 6,389,406.00 · Class: 6.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-045516
Form type
SCHEDULE 13D/A
Filer
Bpifrance Participations SA
CIK
CIK 1581835
Filed
May 07, 2025
Reporting period
Apr 25, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub